STERIS stock reports 7.3 percent revenue growth as guidance holds
Article excerpt
Highlighted: the sentence this signal was extracted from
STERIS stock (ISIN IE00BFY8C754) was last at USD 208.54 on the NYSE on October 2, 2026, at 4:00 p.m. ET, down 0.38 percent from USD 209.34. The latest quarterly picture combines 7.3 percent revenue growth with reaffirmed fiscal 2027 adjusted EPS guidance of USD 11.10-11.30. According to Yahoo Finance on September 4, 2026, STERIS reported fiscal first-quarter 2027 revenue of USD 1.49 billion for the quarter ended June 30, 2026, up 7.3 percent year over year. Constant-currency organic revenue increased 6.2 percent, giving the headline growth a measurable operational base. The same report showed adjusted EPS of USD 2.59, up 10.7 percent from USD 2.34 in the prior-year quarter, while GAAP EPS rose to USD 2.04 from USD 1.79. Adjusted EPS exceeded the consensus estimate by 1.97 percent, but revenue missed consensus by 0.83 percent, creating a mixed comparison beneath the stronger earnings figure. Yahoo Finance reported that STERIS reiterated fiscal 2027 as-reported revenue growth guidance of 7-8 percent and constant-currency organic growth guidance of 6-7 percent. Adjusted EPS guidance remained USD 11.10-11.30, so execution against the upper end is the key earnings checkpoint. On October 3, 2026, MarketBeat reported that Wall Street Zen upgraded STERIS from buy to strong-buy. The article also cited a USD 271.33 average analyst target and a Moderate Buy consensus, while Piper...
Keep reading with a free account
The rest of this article, and every signal for Steris, is in your free account.
